UBS downgraded CureVac (CVAC) to Neutral from Buy with a price target of $5.50, down from $12. BioNTech (BNTX) announced the acquisition of CureVac for $5.46 per share, or a total equity value of $1.25B, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC: